OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of “Hold” by Brokerages

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) have been given an average rating of “Hold” by the five analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $6.3333.

A number of research analysts recently issued reports on OKYO shares. Piper Sandler started coverage on OKYO Pharma in a report on Friday, February 20th. They issued an “overweight” rating and a $7.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of OKYO Pharma in a report on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a report on Thursday, January 22nd.

Institutional Trading of OKYO Pharma

A number of institutional investors have recently bought and sold shares of OKYO. Citadel Advisors LLC purchased a new stake in OKYO Pharma during the 3rd quarter worth about $31,000. Renaissance Technologies LLC increased its position in shares of OKYO Pharma by 235.0% during the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after purchasing an additional 96,800 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of OKYO Pharma during the fourth quarter worth about $36,000. 2.97% of the stock is owned by hedge funds and other institutional investors.

OKYO Pharma Trading Down 4.4%

NASDAQ:OKYO opened at $1.51 on Friday. The stock has a fifty day moving average price of $1.72 and a 200 day moving average price of $2.03. OKYO Pharma has a 12-month low of $1.06 and a 12-month high of $3.35.

OKYO Pharma (NASDAQ:OKYO) last released its earnings results on Friday, January 30th. The company reported ($2.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($2.21). As a group, sell-side analysts forecast that OKYO Pharma will post -0.17 earnings per share for the current year.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.